Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro

Inclusion criteria

• Patients with hematologic malignancies who have been subjected to allo-HSCT and that are diagnosed with one or more peripheral cytopenias with complete chimerism in bone marrow (determined by molecular-STR-studies). They may include:

• Patients who have received as a source of cells MO or SP
• Patients who have received cells from a related donor or unrelated HLA-matched
• Patients transplanted with myeloablative or non-myeloablative conditioning
• Adequate cardiac function assessed from a clinical point of view by the researcher, with no history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months.
• Adequate pulmonary function assessed clinically without evidence of severe obstructive or restrictive lung disease.
• Patients between 18 and 70 years
• Signed informed consent

Exclusion criteria

• Patients whose haemopathy has not been controlled by the transplantation or is in progress at the time of treatment.
• Patients who do not have complete chimerism in bone marrow (performed within 28 days prior to baseline by molecular study -STR-).
• Patients with thrombotic microangiopathy.
• Patients with post-transplant cytopenias with toxic origin in relation to antiviral treatment (eg ganciclovir, valganciclovir) without concomitant graft against host disease.
• Patients with bacterial, viral or fungal infection that is not being controlled with proper treatment.
• Patients with a history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months, and those considered by the investigator does not have adequate cardiac function, evaluated from a clinical point of view.
• Patients with poor lung function, evaluated clinically, according to the researcher.
• Patients who, in the opinion of the investigator, are not on a good position to tolerate treatment.
• Patients who do not have the required donor.
• Women pregnant or at risk of pregnancy by contraceptive measures inadequate.
• Patients <18 or > 70 years.
• Patients who did not sign the informed consent.